FTD–Motor Neuron Disease Spectrum
The clinical overlap between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) represents one of the most important conceptual advances in neurodegeneration. Approximately 15% of patients with FTD develop motor neuron disease, and up to 30% of patients with ALS demonstrate cognitive or behavioral impairment meeting FTD criteria. The discovery of C9orf72 hexanucleotide repeat expansions as a shared genetic cause, and TDP-43 as a unifying neuropathological substrate, has firmly established FTD and ALS as opposite ends of a continuous disease spectrum. This spectrum extends further to include progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), which share phenotypic and pathologic overlap with the core FTD syndromes through atypical parkinsonian features.
Bottom Line
- Continuous spectrum: FTD and ALS are not separate diseases but poles of a clinicopathological continuum linked by shared genetics (C9orf72, FUS, TBK1) and TDP-43 proteinopathy
- FTD-MND overlap: Occurs in ~15% of FTD and ~30% of ALS patients; behavioral variant FTD is the most common cognitive phenotype, though nonfluent and semantic PPA variants also occur
- C9orf72: The hexanucleotide GGGGCC repeat expansion is the most common genetic cause of both familial FTD and familial ALS, accounting for ≥25% of familial cases of each
- Prognosis: FTD-ALS carries a significantly worse prognosis than either condition alone, with median survival of 2–3 years from symptom onset
- Cognitive screening: All ALS patients should undergo cognitive and behavioral screening (e.g., Edinburgh Cognitive and Behavioural ALS Screen) given the high rate of subclinical impairment
- PSP and CBS: These atypical parkinsonian syndromes share tau-based pathologic overlap with FTD and represent additional nodes on the broader FTLD spectrum
The FTD-ALS Continuum
The association between FTD and ALS was first noted in the late 19th century, but the molecular basis of this overlap was not understood until the discovery of TDP-43 as a shared pathological protein in 2006 and the identification of C9orf72 expansions in 2011. The FTD-ALS spectrum encompasses a range of presentations from pure behavioral/cognitive syndromes at one end to pure motor neuron disease at the other, with most patients falling somewhere along this continuum.
Clinical Features of FTD-MND
- Behavioral changes: Disinhibition, apathy, loss of empathy, compulsive behaviors, and dietary changes typically accompany or precede motor symptoms
- Upper motor neuron signs: Spasticity, hyperreflexia, extensor plantar responses, pseudobulbar affect
- Lower motor neuron signs: Fasciculations, muscle atrophy, weakness (often asymmetric), reduced reflexes in atrophic segments
- Bulbar dysfunction: Dysarthria, dysphagia, tongue fasciculations — often an early and prominent feature in FTD-ALS
- Executive dysfunction: Impaired planning, set-shifting, and verbal fluency; may be the earliest cognitive finding in ALS patients
- Language involvement: Nonfluent variant PPA and, less commonly, semantic variant PPA may coexist with motor neuron disease
- Psychotic features: Delusions (persecutory, somatoform) are more common in C9orf72-associated FTD-ALS than in sporadic forms
Cognitive Screening in ALS
Given that up to 50% of ALS patients have measurable cognitive or behavioral impairment and ~15% meet full FTD criteria, routine screening is essential. The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) is specifically designed for patients with motor impairment, testing ALS-specific domains (executive function, language, verbal fluency) and ALS-nonspecific domains (memory, visuospatial function). Unlike the Montreal Cognitive Assessment, the ECAS minimizes reliance on motor output and can be administered even to patients with significant limb or bulbar weakness.
TDP-43: The Unifying Proteinopathy
Transactive response DNA-binding protein 43 (TDP-43) is an RNA/DNA-binding protein that, in disease states, becomes hyperphosphorylated, ubiquitinated, and mislocalized from the nucleus to the cytoplasm, forming pathological aggregates. TDP-43 pathology is found in approximately 50% of all FTD cases and >95% of ALS cases, making it the principal molecular link between these conditions.
| TDP-43 Subtype | Pathological Features | Associated Clinical Syndromes | Genetic Associations |
|---|---|---|---|
| Type A | Neuronal cytoplasmic inclusions in cortical layer II; short, thick dystrophic neurites | Behavioral variant FTD, nonfluent variant PPA | GRN mutations, C9orf72 |
| Type B | Diffuse granular neuronal cytoplasmic inclusions across all cortical layers and hippocampal dentate | FTD-ALS, behavioral variant FTD | C9orf72 (most common) |
| Type C | Long dystrophic neurites in superficial cortical layers; hippocampal neuronal cytoplasmic inclusions | Semantic variant PPA | Usually sporadic |
| Type D | Intranuclear inclusions with dystrophic neurites | Inclusion body myopathy with Paget disease and FTD | VCP mutations |
Concomitant motor neuron disease in a patient with behavioral variant FTD strongly suggests TDP-43 pathology, particularly type B. This clinicopathological correlation is one of the most reliable in the FTD spectrum and has direct implications for genetic counseling and future targeted therapies.
Genetics of the FTD-ALS Spectrum
C9orf72 Hexanucleotide Repeat Expansion
The GGGGCC hexanucleotide repeat expansion in the noncoding region of C9orf72 is the most common genetic cause of both familial FTD (~25%) and familial ALS (~40%). It is inherited in an autosomal dominant pattern with incomplete penetrance. Three pathogenic mechanisms have been proposed: loss of C9orf72 protein function, RNA toxicity from sense and antisense repeat transcripts forming nuclear foci, and production of toxic dipeptide repeat proteins through repeat-associated non-ATG (RAN) translation.
Clinical Features of C9orf72-Associated Disease
- Mean age of onset: ~58–61 years, later than MAPT mutations but variable
- Phenotypic range: Pure FTD, pure ALS, FTD-ALS, and rarely parkinsonism or cerebellar ataxia
- Psychiatric features: Delusions (persecutory, somatoform), hallucinations — more common than in other FTD genetics
- Late parkinsonism: May develop during the disease course, adding diagnostic complexity
- Imaging: Relatively symmetric, frontal-predominant atrophy; may show global and anterior > posterior pattern
- Pathology: TDP-43 type A, type B, or mixed; distinctive p62-positive dipeptide repeat inclusions in the cerebellum and hippocampus
- Presymptomatic biomarkers: Plasma neurofilament light chain begins to exceed normal levels ~30 years before symptom onset; temporal lobe volume loss detectable ~6 years before onset
Other Genetic Causes
| Gene | Protein | Pathology | Clinical Phenotype | Key Features |
|---|---|---|---|---|
| C9orf72 | C9orf72 | TDP-43 (A/B) | FTD, ALS, FTD-ALS | Most common genetic FTD-ALS; psychotic features; repeat expansion |
| GRN | Progranulin | TDP-43 (A) | bvFTD, nfvPPA, CBS | Asymmetric atrophy; no MND association; highly variable phenotype within families |
| MAPT | Tau | Tau (3R or 4R) | bvFTD, PSP, CBS, svPPA | Youngest onset (~49y); disinhibition; temporal atrophy; H1 haplotype risk for PSP/CBD |
| FUS | FUS | FUS | bvFTD, ALS (juvenile) | ~5% of FTLD; very young onset possible (as young as 22y); caudate atrophy |
| TBK1 | TBK1 | TDP-43 | ALS, FTD-ALS | Emerging cause of FTD-ALS; involved in autophagy and neuroinflammation |
| SQSTM1 | p62/Sequestosome-1 | TDP-43 | ALS, FTD, Paget disease | Role in selective autophagy; rare but links FTD-ALS with bone disease |
| VCP | Valosin-containing protein | TDP-43 (D) | FTD, myopathy, Paget disease | Multisystem proteinopathy; inclusion body myopathy |
Progressive Supranuclear Palsy
Progressive supranuclear palsy (PSP) is a 4R tauopathy that lies on the broader FTD spectrum. It presents with atypical parkinsonism and variable cognitive and behavioral features. PSP is pathologically characterized by globose neurofibrillary tangles in subcortical nuclei (subthalamic nucleus, substantia nigra), tufted astrocytes, and oligodendroglial coiled bodies. Atrophy predominantly affects the midbrain and thalamus, with relatively little cortical involvement compared to other FTLD conditions.
PSP Clinical Variants
- Richardson syndrome (PSP-RS): The classic and most common phenotype; early postural instability with backward falls, vertical supranuclear gaze palsy (especially downgaze), symmetric axial rigidity, frontal cognitive dysfunction, and poor levodopa response
- PSP-Parkinsonism (PSP-P): Asymmetric parkinsonism with moderate levodopa response initially; progresses to resemble PSP-RS over time
- PSP-Progressive gait freezing (PSP-PGF): Early gait freezing without other parkinsonian or cognitive features
- PSP-Frontal (PSP-F): Prominent behavioral variant FTD features (apathy, disinhibition, executive dysfunction) with later development of motor features
- PSP-Speech/Language (PSP-SL): Nonfluent progressive aphasia or progressive apraxia of speech as the leading feature
- PSP-CBS: Asymmetric limb apraxia, dystonia, and cortical sensory loss mimicking corticobasal syndrome
Corticobasal Syndrome and Corticobasal Degeneration
Corticobasal syndrome (CBS) is a clinical diagnosis defined by asymmetric rigidity, cortical dysfunction (ideomotor apraxia, alien limb phenomenon, cortical sensory loss), and movement disorders (dystonia, myoclonus). Corticobasal degeneration (CBD) is a specific 4R tauopathy with asymmetric frontal and parietal cortical atrophy, ballooned achromatic neurons, and diffuse phospho-tau immunoreactivity. Importantly, CBS is pathologically heterogeneous — only about 25–50% of patients with CBS have CBD at autopsy; the remainder may have AD, PSP, Pick disease, or TDP-43 pathology.
| Feature | PSP (Richardson Syndrome) | Corticobasal Syndrome | FTD-ALS |
|---|---|---|---|
| Symmetry | Symmetric (axial predominant) | Markedly asymmetric | Variable (often asymmetric weakness) |
| Key motor signs | Vertical gaze palsy, falls, axial rigidity | Limb apraxia, alien limb, dystonia, myoclonus | Fasciculations, wasting, spasticity, bulbar signs |
| Cognitive profile | Frontal-executive; apathy | Apraxia, visuospatial deficits; may present as nfvPPA | Behavioral (disinhibition, apathy); executive dysfunction |
| Predominant pathology | 4R tau (PSP) | Heterogeneous: CBD, AD, PSP, Pick | TDP-43 (type B) |
| Imaging pattern | Midbrain atrophy ("hummingbird sign") | Asymmetric perirolandic and frontoparietal atrophy | Bilateral motor/premotor and frontotemporal atrophy |
| Median survival | 6–9 years | 6–8 years | 2–3 years |
Neuroimaging
Neuroimaging plays a critical role in narrowing the differential diagnosis within the FTD-MND spectrum. Pattern recognition on structural MRI and metabolic PET provides important clues to the underlying pathology.
- FTD-ALS: Bilateral motor and premotor cortex atrophy, middle and inferior frontal gyri, anterior superior frontal gyri, temporal poles, and posterior thalamus; cognitively normal ALS patients show less frontal involvement
- PSP: Midbrain atrophy producing the "hummingbird sign" on sagittal MRI and "morning glory sign" on axial sections; subthalamic nucleus and thalamic involvement
- CBS/CBD: Asymmetric perirolandic atrophy involving frontal and parietal cortex plus striatum and brainstem; cases with AD pathology show greater posterior (parietal) atrophy versus FTLD pathology showing more frontal atrophy
- C9orf72: Relatively symmetric, frontal-predominant, often global atrophy (anterior > posterior); may be striking even in early disease
- FDG-PET: Frontal and anterior temporal hypometabolism distinguishes FTD from AD (posterior temporoparietal hypometabolism); useful when MRI is inconclusive
Prognosis and Disease Course
Prognostic Considerations in FTD-MND
- FTD-ALS has the worst prognosis of any FTD subtype, with median survival of 2–3 years from symptom onset — significantly shorter than either FTD alone (6–11 years) or ALS alone (3–5 years)
- Bulbar onset in FTD-ALS is associated with particularly rapid decline due to early dysphagia and aspiration risk
- Respiratory failure is the most common cause of death, as in pure ALS
- Cognitive impairment in ALS (even without full FTD criteria) independently predicts shorter survival and reduced compliance with interventions such as noninvasive ventilation
- C9orf72 carriers with FTD-ALS may have variable rates of progression; some show a slower cognitive course but aggressive motor decline
- No disease-modifying therapy currently exists for FTD-ALS; symptomatic management (riluzole for ALS component, SSRIs for behavioral symptoms) and supportive care are the mainstays
Biomarkers and Diagnostic Approach
The diagnosis of FTD-MND spectrum disorders relies on integrating clinical features, neuroimaging, electrodiagnostics, genetic testing, and emerging fluid biomarkers.
- EMG/nerve conduction studies: Essential for confirming motor neuron involvement; widespread denervation with fasciculation potentials in a patient with behavioral changes is highly suggestive of FTD-ALS
- Neurofilament light chain (NfL): Elevated in both serum and CSF; particularly high in FTD-ALS; differentiates FTD from primary psychiatric disease; in C9orf72 carriers, levels begin rising ~30 years before symptom onset
- Genetic testing: Should be offered with genetic counseling in all FTD-ALS cases given the high rate of identifiable mutations (~40% have a family history); C9orf72 testing is the highest priority
- Amyloid biomarkers: Negative amyloid PET or low CSF Aβ42/40 ratio helps exclude AD as the underlying cause of a behavioral or language syndrome
- RT-QuIC: Real-time quaking-induced conversion, originally developed for prion diseases, is being explored for detecting TDP-43 and tau seeding activity in CSF
Management Principles
There are currently no disease-modifying treatments for FTD-ALS. Management is multidisciplinary and focuses on symptom control, safety planning, and caregiver support. FTD imposes a greater caregiver burden than AD because of the behavioral and personality changes, younger age of onset, and often prolonged diagnostic delay.
Therapeutic Approach to the FTD-MND Spectrum
- Behavioral symptoms: SSRIs (sertraline, citalopram, fluoxetine) are first-line for disinhibition, compulsions, irritability, and abnormal eating; trazodone for agitation and disordered eating
- Motor neuron disease: Riluzole (modest survival benefit in ALS); edaravone and AMX0035 (limited evidence); noninvasive ventilation for respiratory insufficiency
- Dysphagia management: Speech-language pathology evaluation; dietary modification; consideration of percutaneous gastrostomy when oral intake becomes unsafe
- Avoid cholinesterase inhibitors: Cholinergic function is relatively preserved in FTD; donepezil and rivastigmine may worsen behavior
- Avoid typical antipsychotics: Patients with FTLD pathology are more sensitive to extrapyramidal side effects; if antipsychotics are needed, use atypical agents at the lowest effective dose
- Multidisciplinary ALS clinic: Neurology, pulmonology, nutrition, physical/occupational/speech therapy, social work, palliative care
- Caregiver support: Education about disease trajectory, behavioral strategies using the DICE model (Describe, Investigate, Create, Evaluate), and referral to FTD-specific support organizations
References
- Clark DG. Frontotemporal dementia. Continuum (Minneap Minn). 2024;30(6, Dementia):1642-1672.
- DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245-256.
- Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477.
- Lomen-Hoerth C. Clinical phenomenology and neuroimaging correlates in ALS-FTD. J Mol Neurosci. 2011;45(3):656-662.
- Vinceti G, Olney N, Mandelli ML, et al. Primary progressive aphasia and the FTD-MND spectrum disorders. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3-4):146-158.
- Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord. 2017;32(6):853-864.
- Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503.
- Staffaroni AM, Quintana M, Wendelberger B, et al. Temporal order of clinical and biomarker changes in familial frontotemporal dementia. Nat Med. 2022;28(10):2194-2206.
- Seelaar H, Rohrer JD, Pijnenburg YAL, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82(5):476-486.
- Coughlin DG, Dickson DW, Josephs KA, Litvan I. Progressive supranuclear palsy and corticobasal degeneration. Adv Exp Med Biol. 2021;1281:151-176.
- Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2019;266(8):2075-2086.
- van der Ende EL, Meeter LH, Poos JM, et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol. 2019;18(12):1103-1111.